earnings
confidence high
sentiment neutral
materiality 0.70
Integer Q1 sales up 7% to $311M, adjusted EPS down 20%; guidance raised for Aran Biomedical acquisition
Integer Holdings Corp
2022-Q1 EPS reported
$0.34
revenue$310,912,000
- Sales $311M (+7% YoY); GAAP net income $11M (-47%); adjusted net income $26M (-19%).
- GAAP diluted EPS $0.34; non-GAAP adjusted EPS $0.78, down 20% YoY.
- Acquired Aran Biomedical on April 6, 2022; adds ~$90M annualized sales at accretive growth.
- FY2022 outlook: sales $1.36-1.38B (11-13% growth), adj. EBITDA $273-285M (12-17% growth).
- Cardio & Vascular sales +13%; Cardiac Rhythm +1%; Electrochem +18%; Advanced Surgical -2%.